Sophiris Bio Inchares (NASDAQ:SPHS) Stock Is Shorted Less

June 11, 2018 - By Alfred Lee

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Investors sentiment decreased to 1 in Q1 2018. Its down 1.80, from 2.8 in 2017Q4. It dived, as 5 investors sold Sophiris Bio, Inc. shares while 5 reduced holdings. 5 funds opened positions while 5 raised stakes. 1.63 million shares or 13.01% less from 1.87 million shares in 2017Q4 were reported.
Wells Fargo And Co Mn owns 1,800 shares. Goldman Sachs Gp owns 79,855 shares. Vanguard Gru Inc holds 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS) for 893,514 shares. Lpl Ltd Liability stated it has 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). One Trading Ltd Partnership holds 5,386 shares or 0% of its portfolio. Edge Wealth Limited Liability Com reported 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Blackrock holds 77,077 shares or 0% of its portfolio. Northern has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Virtu Fincl Ltd has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Millennium Mngmt has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 104,627 shares. B & T Dba Alpha invested in 23,228 shares. Commercial Bank Of Mellon Corp holds 0% or 36,890 shares. 1832 Asset Management Ltd Partnership accumulated 210 shares. Geode Cap Limited Liability Corporation reported 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Bank & Trust Of America De has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS).

The stock of Sophiris Bio Inchares (NASDAQ:SPHS) registered a decrease of 3.07% in short interest. SPHS’s total short interest was 1.79 million shares in June as published by FINRA. Its down 3.07% from 1.85 million shares, reported previously. With 295,900 shares average volume, it will take short sellers 6 days to cover their SPHS’s short positions. The short interest to Sophiris Bio Inchares’s float is 6.29%.

The stock increased 2.13% or $0.08 during the last trading session, reaching $3.83. About 648,487 shares traded or 79.33% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has risen 44.13% since June 11, 2017 and is uptrending. It has outperformed by 31.56% the S&P500.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $110.04 million. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Sophiris Bio, Inc. (NASDAQ:SPHS) Ratings Coverage

Among 2 analysts covering Sophiris Bio (NASDAQ:SPHS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio has $700 highest and $600 lowest target. $6.50’s average target is 69.71% above currents $3.83 stock price. Sophiris Bio had 4 analyst reports since January 17, 2018 according to SRatingsIntel. H.C. Wainwright maintained Sophiris Bio, Inc. (NASDAQ:SPHS) on Tuesday, May 15 with “Buy” rating. Piper Jaffray initiated it with “Buy” rating and $700 target in Friday, May 18 report. The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) earned “Buy” rating by H.C. Wainwright on Thursday, March 22. The stock has “Buy” rating by H.C. Wainwright on Wednesday, January 17.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: